Literature DB >> 11377805

Mitochondria as subcellular targets for clinically useful anthracyclines.

K Jung1, R Reszka.   

Abstract

Due to the widespread use of anthracyclines as antitumor agents, a large number of investigations have been reported analyzing clinical and molecular aspects of these quinone antibiotics. While the high affinity of anthracyclines towards chromosomal DNA has been held responsible for their antitumor activity, an increasing amount of data is being accumulated showing that these drugs also target mitochondria thus interfering with major mitochondrial functions. Since this toxicity of anthracyclines towards mitochondria is associated with side effects significantly limiting their chemotherapeutic dose, the corresponding underlying mechanisms need to be understood. Bioenergetic failure, enzyme inhibitions, lipid peroxidations, induction of membrane disorders as well as the initiation of oxidative stress are being attributed to the accumulation of anthracyclines at or inside mitochondria. In this review the wide spectrum of possible mode of actions of these antibiotics leading to mitochondrial dysfunctions will be presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377805     DOI: 10.1016/s0169-409x(01)00128-4

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  32 in total

Review 1.  Mitochondria as a target in treatment.

Authors:  Marie-Céline Frantz; Peter Wipf
Journal:  Environ Mol Mutagen       Date:  2010-06       Impact factor: 3.216

2.  Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.

Authors:  Jingchao Xi; Meng Li; Benxin Jing; Myunggi An; Chunsong Yu; Cameron B Pinnock; Yingxi Zhu; Mai T Lam; Haipeng Liu
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-06       Impact factor: 9.229

3.  Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Authors:  Ashley J Smuder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-08-28       Impact factor: 3.619

4.  An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.

Authors:  Yun Mai; J Jessica Yu; Boris Bartholdy; Zijun Y Xu-Monette; Esther E Knapp; Fei Yuan; Hongshan Chen; B Belinda Ding; Zhihua Yao; Bhaskar Das; Yiyu Zou; Ken He Young; Samir Parekh; B Hilda Ye
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

5.  The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death.

Authors:  Allison M McGee; Diana L Douglas; Yayun Liang; Salman M Hyder; Christopher P Baines
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

6.  The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.

Authors:  Pazit Shaul; Michael Frenkel; Elinor Briner Goldstein; Leonid Mittelman; Assaf Grunwald; Yuval Ebenstein; Ilan Tsarfaty; Micha Fridman
Journal:  ACS Med Chem Lett       Date:  2013-02-04       Impact factor: 4.345

7.  Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Authors:  Salim Khiati; Ilaria Dalla Rosa; Carole Sourbier; Xuefei Ma; V Ashutosh Rao; Leonard M Neckers; Hongliang Zhang; Yves Pommier
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

8.  Doxorubicin-mediated apoptosis in glioma cells requires NFAT3.

Authors:  Sreelatha Gopinath; Sravan K Vanamala; Meena Gujrati; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  Cell Mol Life Sci       Date:  2009-09-27       Impact factor: 9.261

Review 9.  Mitochondrial formation of reactive oxygen species.

Authors:  Julio F Turrens
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

Review 10.  Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions.

Authors:  Valerian E Kagan; Peter Wipf; Detcho Stoyanovsky; Joel S Greenberger; Grigory Borisenko; Natalia A Belikova; Naveena Yanamala; Alejandro K Samhan Arias; Muhammad A Tungekar; Jianfei Jiang; Yulia Y Tyurina; Jing Ji; Judith Klein-Seetharaman; Bruce R Pitt; Anna A Shvedova; Hülya Bayir
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.